Investigating the role of Gag in protease inhibitor susceptibility amongst West African HIV-1 subtypes
RWP Datir - 2020 - discovery.ucl.ac.uk
HIV-1 Gag contributes to susceptibility of protease inhibitors (PIs) in the absence of known
resistance mutations in the protease gene. For the majority of HIV-infected patients …
resistance mutations in the protease gene. For the majority of HIV-infected patients …
Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria
R Datir, K El Bouzidi, P Dakum… - Journal of …, 2019 - academic.oup.com
Objectives Previous work showed that gag-protease-derived phenotypic susceptibility to PIs
differed between HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to …
differed between HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to …
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
Protease inhibitors (PIs) are the second-and last-line therapy for the majority of HIV-infected
patients worldwide. Only around 20% of individuals who fail PI regimens develop major …
patients worldwide. Only around 20% of individuals who fail PI regimens develop major …
Gag-protease sequence evolution following protease inhibitor monotherapy treatment failure in HIV-1 viruses circulating in East Africa
KA Sutherland, RL Goodall, A McCormick… - AIDS research and …, 2015 - liebertpub.com
Abstract Around 2.5 million HIV-infected individuals failing first-line therapy qualify for
boosted protease inhibitor (bPI)-based second-line therapy globally. Major resistance …
boosted protease inhibitor (bPI)-based second-line therapy globally. Major resistance …
Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of HIV-1
K Sutherland - 2014 - discovery.ucl.ac.uk
Recent reports have shown that HIV-1 Gag can directly affect susceptibility to protease
inhibitors (PIs) in the absence of known resistance mutations in protease. Inclusion of co …
inhibitors (PIs) in the absence of known resistance mutations in protease. Inclusion of co …
[HTML][HTML] Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency
KA Sutherland, DA Collier, DT Claiborne, JL Prince… - Scientific reports, 2016 - nature.com
The gag gene is highly polymorphic across HIV-1 subtypes and contributes to susceptibility
to protease inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million …
to protease inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million …
[HTML][HTML] Potential Associations of Mutations within the HIV-1 Env and Gag Genes Conferring Protease Inhibitor (PI) Drug Resistance
NF Maphumulo, ML Gordon - Microbiology Research, 2021 - mdpi.com
An increasing number of patients in Africa are experiencing virological failure on a second-
line antiretroviral protease inhibitor (PI)-containing regimen, even without resistance …
line antiretroviral protease inhibitor (PI)-containing regimen, even without resistance …
Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa
TS Boender, RL Hamers, P Ondoa… - The Journal of …, 2016 - academic.oup.com
Background. As antiretroviral therapy (ART) programs in sub-Saharan Africa mature,
increasing numbers of persons with human immunodeficiency virus (HIV) infection will …
increasing numbers of persons with human immunodeficiency virus (HIV) infection will …
Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy
DN Raugi, RA Smith, S Ba, M Toure… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Protease inhibitor (PI)-based antiretroviral therapy (ART) can effectively suppress HIV-2
plasma load and increase CD4 counts; however, not all PIs are equally active against HIV-2 …
plasma load and increase CD4 counts; however, not all PIs are equally active against HIV-2 …
Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: The CASTLE study 48-week results
M Lataillade, R Yang, MD Mancini… - Journal of the International …, 2008 - Springer
Background HIV viral diversity and baseline (BL) substitutions have implications for
response to antiretroviral therapy, the development of resistance and disease progression …
response to antiretroviral therapy, the development of resistance and disease progression …